Status:
COMPLETED
Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the addition of bevacizumab to Abraxane as second-line therapy in Her-2 negative, hormone receptor negative metastatic breast cancer.
Eligibility Criteria
Inclusion
- Female, aged 18 years or older and able to give informed consent.
- Histologically- or cytologically-proven adenocarcinoma of the breast at time of first diagnosis
- ECOG performance status 0 or 1
- Life expectancy \> 12 weeks
- Stage IV disease and have at least one lesion measurable by standard RECIST criteria
- Disease progression after at least one prior chemotherapy regimen for metastatic disease or within 12 months of adjuvant chemotherapy initiation.
- All chemotherapy must be stopped \> 2 weeks before enrollment.
- Primary or metastatic tumor must be negative for estrogen and progesterone receptor expression. Testing must be done in a CLIA-approved laboratory.
- Primary or metastatic tumor must have 0 or 1+ staining for HER2/neu identified immunohistochemically (IHC), by an approved method using one of the standard monoclonal or polyclonal antibodies (HercepTest, cb-11, PAb1, or TAB250), or if FISH status is known, it must be negative. Testing must be done in a CLIA-approved laboratory.
- Left ventricular ejection fraction must be \>= institutional lower limit of normal as determined by MUGA or echocardiogram
- Patient must be able to comply with treatment and follow-up procedures:
- Adequate bone marrow, liver and renal function; Absolute neutrophil count \>= 1500/mm3; Hemoglobin \>= 10 g/dl; Platelet count \>= 100,000/mm3; Creatinine \<= 2.0; PTT and either INR or PT \< 1.5x normal; Total bilirubin \<= 1.5 X upper limit of normal; AST, ALT, and alkaline phosphatase \<= 2 X upper limit of normal (or \<= 5X upper limit of normal if known liver metastases)
- If female is of childbearing potential, pregnancy test must be negative and patient must be willing to use effective contraception while on treatment and for at least 3 months after the last dose of study medication
Exclusion
- Prior treatment with VEGF targeted therapy
- Prior taxane therapy for metastatic disease or for adjuvant therapy within the previous 12 months
- History of prior cancer, excluding carcinoma in situ of the cervix and non-melanoma skin cancers
- Known CNS disease
- Inadequately controlled hypertension (defined as systolic blood pressure\>150 and/or diastolic blood pressure\>100 mmHg on antihypertensive medications)
- Any prior history of hypertensive crisis or hypertensive encephalopathy
- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- History of myocardial infarction or unstable angina within 6 months prior to study enrollment
- History of stroke or transient ischemic attack within 6 months prior to study enrollment
- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
- Symptomatic peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment
- Serious, non-healing wound, ulcer or bone fracture
- Proteinuria at screening as demonstrated by either: Urine protein:creatinine (UPC) ratio \>1.0 at screening OR Urine dipstick for proteinuria \>2+ (patients discovered to have \>2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \<1g of protein in 24 hours to be eligible)
- Patients with active infection
- Women who are pregnant or lactating
- Radiation therapy within 3 weeks of study entry
- Patients with hypersensitivity to ABI-007, Chinese hamster ovary cell products, or other recombinant human antibodies
- Baseline neuropathy \> grade 2
- Participation in an investigational study of an antineoplastic agent within 4 weeks of first infusion of this study.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00472693
Start Date
May 1 2007
End Date
April 1 2011
Last Update
April 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center at University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104